Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11454684 | 0.83 | TDP1 (0.59) | ERN1GPR35TDP1ALDH5A1ABAT | |
| SCHEMBL4497809 | 0.83 | ERN1 (0.70) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL16838215 | 0.80 | ERN1 (0.61) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL7368834 | 0.79 | ERN1 (0.56) | ERN1GPR35XDH | |
| SCHEMBL14092109 | 0.79 | ERN1 (0.59) | ERN1GPR35TDP1XDHALDH5A1 | |
| Bicarbonate SCHEMBL27618577 | 0.77 | ERN1 (0.62) | ERN1GPR35XDHALDH5A1ABAT | |
| SCHEMBL31170798 | 0.77 | TDP1 (0.67) | ERN1GPR35TDP1VCAM1 | |
| SCHEMBL10434405 | 0.77 | GPR35 (0.57) | ERN1GPR35TDP1ALDH5A1ABAT | |
| SCHEMBL5595026 | 0.77 | TDP1 (0.67) | ERN1GPR35TDP1VCAM1 | |
| SCHEMBL1527066 | 0.76 | ERN1 (0.61) | ERN1GPR35XDHALDH5A1ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415767-B1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| US-4584318-A | FOR AGRICULTURAL CROPS | FMC CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | ERN1 1074/4885GPR35 4412/4885TDP1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.